SEOUL, South Korea — Options trading is likely to be a key bet among institutional investors in cryptocurrencies than other niches such as decentralized finance (DeFi) or non-fungible token finance (NFTfi) in the coming years, according to prominent crypto fund QCP Capital.
“DeFi has been big, GameFi has been big and options have always taken a backseat,” Darius Sit, QCP Capital co-founder, said at a Korean Blockchain Week panel here attended by CoinDesk. “But this year, and going forward, is going to be more interesting because the space is getting more institutional.”
Options are popular among professional traders because they give the buyer the right – but not the obligation – to buy or sell the underlying asset at a specific price on or before a certain date. These products can be used to lay speculative bets and hedge risk.
Sit argued that institutions were likely to adopt a financial instrument, such as an option, that was much more conversant compared with niche on-chain tools or non-fungible token (NFT)-based financial platforms.
“The first stop for them is usually [options] because for them it's is the same product, same instrument, same market structure, just different underlying. And so options and futures become a very big first of all for them,” Sit said.
The ex-BNP Paribas trader said “big name” banks are coming in and starting to “dominate" options flow: “These guys used to do billions or trillions in forex. Now they're doing it in crypto,” he said.
As for the preferred venue to trade such products, Sit said institutions were likely to use centralized exchanges over their decentralized counterparts for the former’s ease of onboarding, settlements and overall distribution channels.
QCP Capital is a major player in the crypto options market, doing billions of dollars in trading volumes monthly. That’s a significant chunk of total crypto options volumes, with some $12 billion worth of options traded in July alone, data shows.
While bitcoin (BTC) options have historically dominated the market, ether (ETH) options recently flipped the former for the first time ahead of September’s expected Merge event as investors turned bullish on ether’s long-term prospects, as previously reported.
Rapper Coolio, most famous for his hit song "Gangsta's Paradise," died at age 59 on Sept. 28, TMZ reported. At the time of his death, the performer held an estimated net worth of $1.5 million,…
Leaving these accounts open could tarnish your golden years.
The bear market in software stocks has already lasted far longer than the typical decline, according to MoffettNathanson,
Yahoo Finance Live examines Carnival Cruise's stock after its latest earnings miss signifies a much longer path to profitability than expected.
September is living up to its reputation as an ugly month for stocks. Here's what the data says about October performance.
Yahoo Finance Live anchors discuss stock performance for cruise lines.
Inflation, interest rates, and recession – these are the bogeymen of investing, and they’ve been watching over our shoulders for the past several months. We all know the story by now, the rate of inflation is running at generational highs, the Federal Reserve is hiking rates in an attempt to push back against high prices, and that’s likely to tip the economy into recession. At a time like this, investors are showing a growing interest in finding strong defensive portfolio moves. It’s a mindset t
Tesla CEO Elon Musk promised last year to have a working prototype of the Optimus robot ready to show off at AI Day 2022. On Friday, he debuted one.
Billionaire investor Stanley Druckenmiller sees a “hard landing” by the end of 2023 as the Federal Reserve’s aggressive monetary tightening will tip the U.S. economy into recession.
Semiconductor stocks have tumbled in recent months amid flagging demand, with the S&P Semiconductors Select Industry Index dropping 36% year to date. Bank of America analysts recently discussed their favorite choices in the sector.
Tesla unveiled its first prototype of its Optimus humanoid robot on Friday — an actual robot this time, by the strictest definition, instead of a flesh and blood human clad in a weird suit. The robot performed some basic functions, including walking a little bit and then raising its hands — all for the first time without supports or a crane, according to Tesla CEO Elon Musk. The company may be taking its first early steps into humanoid robotics, but it has a lot riding on the business.
Shares of Annaly Capital Management (NYSE: NLY) were among the losers this week as rising mortgage rates threatened to squeeze the mortgage REIT, and one analyst expressed caution on the stock. The company also executed a reverse stock split at the beginning of the week. Since the rate hike, which came with hawkish commentary from Fed Chair Jerome Powell, investors seem to believe the risk of a recession has grown, as well as the likelihood of a sustained high-interest-rate environment.
Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session.
Warren Buffet's mentor Benjamin Graham is famous for insisting that investors look at large declines in the stock market as a discount or sale, rather than panic. Here's a look at two quality tech stocks that have a chance to go back to their previous highs once macroeconomic conditions stabilize.
The Dow Jones is at bear market lows. Tesla showed off the Optimus robot at AI Day. Tesla deliveries are on tap, with China EV rival Li Auto topping forecasts.
Portfolio Wealth Advisors President and CIO Lee Munson and Sound Planning Group CEO David Stryzewski join Yahoo Finance Live to discuss the recent market volatility, inflation, rising rates, and more.
Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. ET Friday morning. The biotech's stock appears to be getting a boost from both a broad upward trend across the biotechnology space today, as well as from rumors circulating on social media about a possible buyout. Bluebird scored two approvals from the Food and Drug Administration (FDA) earlier this year for its one-and-done gene therapies: Skysona for cerebral adrenoleukodystrophy (CALD) and Zynteglo for transfusion-dependent beta-thalassemia (TDT).